Interleukin 35 Delays Hindlimb Ischemia-Induced Angiogenesis Through Regulating ROS-Extracellular Matrix but Spares Later Regenerative Angiogenesis.

Hangfei Fu
Temple University

Yu Sun
Temple University

Ying Shao
Temple University

Jason Saredy
Temple University

Ramon Cueto
Temple University

See next page for additional authors.

Follow this and additional works at: https://jdc.jefferson.edu/transmedfp

Recommended Citation
Fu, Hangfei; Sun, Yu; Shao, Ying; Saredy, Jason; Cueto, Ramon; Liu, Lu; Drummer, Charles; Johnson, Candice; Xu, Keman; Lu, Yifan; Li, Xinyuan; Meng, Shu; Xue, Eric R; Tan, Judy; Jhala, Nirag C; Yu, Daohai; Zhou, Yan; Bayless, Kayla J; Yu, Jun; Rogers, Thomas J; Hu, Wenhui; Snyder, Nathaniel W; Sun, Jianxin; Qin, Xuebin; Jiang, Xiaohua; Wang, Hong; and Yang, Xiaofeng, "Interleukin 35 Delays Hindlimb Ischemia-Induced Angiogenesis Through Regulating ROS-Extracellular Matrix but Spares Later Regenerative Angiogenesis." (2020). Center for Translational Medicine Faculty Papers. Paper 75.
https://jdc.jefferson.edu/transmedfp/75
Authors
Hangfei Fu, Yu Sun, Ying Shao, Jason Saredy, Ramon Cueto, Lu Liu, Charles Drummer, Candice Johnson, Keman Xu, Yifan Lu, Xinyuan Li, Shu Meng, Eric R Xue, Judy Tan, Nirag C Jhala, Daohai Yu, Yan Zhou, Kayla J Bayless, Jun Yu, Thomas J Rogers, Wenhui Hu, Nathaniel W Snyder, Jianxin Sun, Xuebin Qin, Xiaohua Jiang, Hong Wang, and Xiaofeng Yang

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/transmedfp/75
Interleukin 35 Delays Hindlimb Ischemia-Induced Angiogenesis Through Regulating ROS-Extracellular Matrix but Spares Later Regenerative Angiogenesis

Hangfei Fu1, Yu Sun1†, Ying Shao1†, Jason Saredy2†, Ramon Cueto2, Lu Liu2, Charles Drummer IV1, Candice Johnson3, Keman Xu1, Yifan Lu1, Xinyuan Li1, Shu Meng3, Eric R. Xue1, Judy Tan1, Niral G. Jhala4, Daohai Yu5, Yan Zhou6, Kayla J. Bayless7, Jun Yu2, Thomas J. Rogers8, Wenhui Hu2, Nathaniel W. Snyder2, Jianxin Sun9, Xuebin Qin10, Xiaohua Jiang1,2,8, Hong Wang2 and Xiaofeng Yang1,2,8*

1 Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States, 2 Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research, Departments of Pharmacology, Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States, 3 Center for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States, 4 Department of Pathology & Laboratory Medicine Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States, 5 Department of Clinical Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States, 6 Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, United States, 7 Department of Molecular and Cellular Medicine, Texas A&M University College of Medicine, College Station, TX, United States, 8 Center for Inflammation, Translational and Clinical Lung Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States, 9 Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, United States, 10 National Primate Research Center, Tulane University, Covington, LA, United States

Interleukin (IL) 35 is a novel immunosuppressive heterodimeric cytokine in IL-12 family. Whether and how IL-35 regulates ischemia-induced angiogenesis in peripheral artery diseases are unrevealed. To fill this important knowledge gap, we used loss-of-function, gain-of-function, omics data analysis, RNA-Seq, in vivo and in vitro experiments, and we have made the following significant findings: i) IL-35 and its receptor subunit IL-12RB2, but not IL-6ST, are induced in the muscle after hindlimb ischemia (HLI); ii) HLI-induced angiogenesis is improved in Il12rb2−/− mice, in ApoE−/−/Il12rb2−/− mice compared to WT and ApoE−/− controls, respectively, where hyperlipidemia inhibits angiogenesis in vivo and in vitro; iii) IL-35 cytokine injection as a gain-of-function approach delays blood perfusion recovery at day 14 after HLI; iv) IL-35 induced angiogenesis is improved in Il12rb2−/− mice, in ApoE−/−/Il12rb2−/− mice compared to WT and ApoE−/− controls, respectively, where hyperlipidemia inhibits angiogenesis in vivo and in vitro; v) IL-35 cytokine injection as a gain-of-function approach delays blood perfusion recovery at day 14 after HLI; iv) IL-35 spares regenerative angiogenesis at the late phase of HLI recovery after day 14 of HLI; v) Transcriptome analysis of endothelial cells (ECs) at 14 days post-HLI reveals a disturbed extracellular matrix re-organization in IL-35-injected mice; vi) IL-35 downregulates three reactive oxygen species (ROS) promoters and upregulates one ROS attenuator, which may functionally mediate IL-35 upregulation of anti-angiogenic extracellular matrix proteins in ECs; and vii) IL-35 inhibits human microvascular EC migration and tube formation in vitro mainly through upregulating anti-angiogenic extracellular matrix-remodeling proteins. These findings provide a novel

OPEN ACCESS

Edited by:
Francesca Granucci,
University of Milano-Bicocca, Italy

Reviewed by:
Devendra K. Agrawal,
Western University of Health Sciences,
United States
Shyou Chen,
University of Missouri, United States

*Correspondence:
Xiaofeng Yang
xfyang@temple.edu

†These authors have contributed equally to this work

Specialty section:
This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology

Received: 17 August 2020
Accepted: 22 September 2020
Published: 14 October 2020

Citation:
Fu H, Sun Y, Shao Y, Saredy J, Cueto R, Liu L, Drummer C IV, Johnson C, Xu K, Lu Y, Li X, Meng S, Xue ER, Tan J, Jhala NC, Yu D, Zhou Y, Bayless KJ, Yu J, Rogers TJ, Hu W, Snyder NW, Sun J, Qin X, Jiang X, Wang H and Yang X (2020) Interleukin 35 Delays Hindlimb Ischemia-Induced Angiogenesis Through Regulating ROS-Extracellular Matrix but Spares Later Regenerative Angiogenesis. Front. Immunol. 11:595813. doi: 10.3389/fimmu.2020.595813
Peripheral arterial disease (PAD) is a vascular pathology where narrowed arteries reduce blood flow to the peripheral extremities and organs such as legs, arms, and head. The most common symptom of PAD is leg pain, particularly when walking. PAD is highly associated with coronary artery disease and stroke (1), which are the leading causes of death worldwide. They are caused by atherosclerosis, where the plaques build-up in the artery wall, a common condition in the aging population. It is estimated that more than 200 million people have PAD worldwide (1). Although the current gold standard treatment for advanced PAD patients is surgical revascularization, there are no effective therapies for many patients with advanced conditions who are not candidates for surgery (2). Also, better recovery from surgical revascularization largely relies on angiogenesis in adjacent ischemic tissue. Thus, novel therapies such as pro-angiogenic therapy to improve neovascularization are urgently desired.

Since Dr. Vignali’s team reported the contribution of novel cytokine interleukin-35 (IL-35) to CD4+ Foxp3+ regulatory cell (Treg) function in 2007 (3), significant progress has been made with 629 publications on PubMed. We reported that IL-35 is a new responsive heterodimeric anti-inflammatory cytokine (4). IL-35 belongs to the IL-12 cytokine family and is potent in inhibiting various inflammatory diseases including lipopolysaccharide (LPS)-induced lung inflammation, human aortic endothelial cell (HAEC) activation (5), atherogenic lipids lysophosphatidylcholine (LPC) (6-8)-induced HAEC activation and atherosclerosis (9) but sparing innate immune memory (trained immunity) in HAEC (8, 10-12) as we reported. IL-35 α-chain p35 (encoded by IL12A) is shared with IL-12; and β-chain EBI3 (encoded by Epstein–Barr virus-induced 3, EBI3) is shared with IL-27 and IL-39. IL-35 receptor (IL35R) subunit IL-12Rβ2 (encoded by IL12RB2) is shared with IL-12 receptor; and IL35R subunit IL-6 signal transducer (IL6ST, gp130) is shared with IL-27 and IL-39 receptors. In addition, EBI3 receptor IL6ST is also shared with IL-6 superfamily, where the IL-12 family belongs. IL-35 signaling is unconventional because it has multiple forms of receptors and presents cell-specificity, as we reviewed (13). It can bind not only to heterodimeric receptor IL-6ST-IL-12Rβ2, but also two homodimers such as: i) IL-6ST-IL-6ST, and ii) IL-12Rβ2-IL-12Rβ2, which then activates signal transducer and activator of transcription 1 (STAT1) and STAT4 in Treg (13). The same study also shows that maximal anti-inflammatory function requires the heterodimeric receptor (5). However, the following study shows that in regulatory B cells (Breg), IL-35 signals through a heterodimer of IL-12Rβ2 and IL-27Rα and activates STAT1 and STAT3 (14). Unlike other members in the IL-12 family that are secreted mainly by activated antigen-presenting cells (dendritic cells, monocyte/macrophages, and B cells), IL-35 is predominantly secreted by Treg (15) and Breg. To a less extent, it has been predicted to be secreted by other cell types including endothelial cells (ECs) (4).

Angiogenesis is the process of new capillary formation from pre-existing vessels. Inflammation, angiogenesis, and extracellular matrix (ECM) remodeling are often coupled in pathological conditions (16). Inflammation drives angiogenesis by direct and indirect mechanisms, promoting EC proliferation, migration, and vessel sprouting, but also by mediating extracellular matrix remodeling and release of sequestered growth factors, and recruitment of proangiogenic leukocyte subsets (17). In chronic inflammation, the formation of new blood vessels results in an increased endothelial surface area, which further facilitates inflammatory cell migration (18) into the inflamed tissue through vasodilatation and increased endothelial cell permeability (19). Although ECs are the most important cell types (20) in the angiogenic process, immune cell infiltration is critical for angiogenesis in the early stage of ischemia; although sustained inflammation can also lead to delayed angiogenesis (21) or undesired vessel overgrowth (22). Hindlimb ischemia represents a complex model with ischemia-induced necrosis and inflammation, ischemia-induced angiogenesis, arteriogenesis and skeletal muscle regeneration (23). In comparison, scarless wound healing in fetuses has been associated with a short-lived and less robust inflammatory response (21). Thus, anti-inflammatory cytokines are key regulators in balancing the local inflammation and promote functional neovascularization. IL-35 is expressed in many tumor cell lines, and promotes tumor angiogenesis and progression (24-26). However, it has also been shown that IL-35 over-expression increases apoptosis sensitivity and inhibits cell proliferation in human cancer cells (27). Besides, IL-35 inhibits angiogenesis in rheumatoid arthritis, where one study showed that IL-35 can directly inhibit human umbilical vein endothelial cells (HUVECs) angiogenic activities (28). However, the roles of IL-35 in angiogenesis in ischemic vascular diseases are unrevealed.

Mechanistically, angiogenesis involves several biological events, including extracellular matrix (ECM) degradation, pericyte detachment, EC proliferation, migration, and sprouting, the fusion of tip cells, lumen formation, pericyte reattachment, ECM redepsoition, and vascular remission and stabilization. Each event requires a balance between pro-angiogenic and anti-angiogenic factors, which is by large mediated by ECM proteins and proteases. Integrins are transmembrane proteins that bind to many types of ECM proteins. They are required for focal adhesion (cell-ECM...
adhesion) formation that mechanically connects intracellular actin bundles and the extracellular substrate (29). Focal adhesion also bi-directionally transmits molecular signals, and is essential for a variety of cellular activities including cell adhesion, migration, differentiation, and survival (30). In mammals, ECM is a highly dynamic structure composed of ~300 main proteins, including 43 collagen subunits, 36 proteoglycans, and ~200 glycoproteins (31). It provides not only physical support for vascular integrity but also mediates cellular functions such as proliferation and migration. On the other side, matrix metalloproteinases (MMPs), a disintegrin and metalloproteinases (ADAM) and ADAM with thrombospondin motifs (ADAMTS) are the major proteases that collectively can degrade all known ECM components. Thus, they are critical in regulating ECM remodeling during angiogenesis.

Reactive oxygen species (ROS) play an important role in modulating angiogenesis. Low cellular levels of ROS are usually maintained by systems of antioxidant enzymes and their substrates, such as thioredoxin systems (Trx1 and 2) (32). It has been reported that cardiac-specific Trx2 knockout mice recently demonstrated that suppression of mitochondrial ROS can preserve cardiac function by inhibiting apoptosis signal regulating kinase-1-mediated apoptosis (33). However, mitochondrial oxidants can induce phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), resulting in activation of the receptor and subsequent angiogenesis. Similar to those findings, our previous reports showed that i) IL-35 inhibits lipopolysaccharide (LPS) and proatherogenic lipids LPC induced HAEC activation (5, 7); ii) IL-35 suppresses vascular inflammation and atherosclerosis via inhibiting mitochondrial ROS(8, 9, 34–37); iii) hypoxia may induce thrombus leukocyte transdifferentiation by upregulating endothelial cell-specific angiogenic markers (38); and iv) inhibition of caspase-1/ inflammasome activation in EC improves ischemia-triggered angiogenesis (39, 40). However, the question remained whether IL-35 modulates ischemia-triggered angiogenesis potentially via a ROS-related mechanism.

In this study, we examined a novel hypothesis that IL-35 modulates ischemia-induced angiogenesis through activating integrins and regulating ECM macromolecules. We further hypothesized that IL-35 may dysregulate the core complex of EC-specific adhesion junction (AJ, cell-cell adhesion), which is composed of vascular endothelial cadherin (VE-cadherin), p120-catenin, β-catenin or plakoglobin (also known as γ-catenin), and α-catenin (actin-binding protein). This cadherin-based AJ regulates the intracellular actin-myosin network and is essential for vascular integrity (41, 42). In our study, we used both gain-of-function (IL-35 recombinant protein injection) and loss-of-function (Il12rb2−/−) mouse models to examine the role of IL-35 in ischemia/hypoxia-induced angiogenesis. Protein array and transcriptome analysis were used to explore the underlying molecular mechanisms. Our results have demonstrated for the first time that IL-35 induces ECM remodeling proteins, which leads to the delayed EC migration and tube formation in vitro, and the early phase of HLI-induced angiogenesis in vivo but spare regenerative angiogenesis at late phase. These findings provide a novel insight on the future therapeutic potential of IL-35 in suppressing ischemia/inflammation-triggered angiogenesis but sparing regenerative angiogenesis.

**MATERIALS AND METHODS**

**Reagents and Antibodies**

Recombinant human vascular endothelial growth factor VEGF165 (PeproTech, #100-20), and basic fibroblast growth factor factor (FGF2) (PeproTech, #100-18B) were reconstituted in 0.1% bovine serum albumin (BSA)/phosphate-buffered saline (PBS).

Recombinant mouse IL-35 Fc chimera (Adipogen, #CHI-MF-11135-C025) was reconstituted in sterile PBS. Recombinant human IL-35 Fc chimera (Enzo, #ALX-522-140-C010) was reconstituted in sterile water. Antibodies used against human in western blot: anti-hypoxia-inducible factor-1a (HIF-1a) (BD, #610958), anti-PEDF (Santa Cruz BioTechnology, #sc-390172), anti-β-Actin antibody (Sigma #A5441). Antibodies against mouse used in flow cytometry: anti-CD45.1 APC-Cy7 (BioLegend, #110716), anti-CD45 45 aliphycocyanin-cyanine dye 7 (APC-Cy7) (BioLegend, #103116), anti-CD45.2 R-phycocerythrin-Cy7 (PE-Cy7) (eBioscience, #25-0454-82), anti-CD11b BV421 (BD, #562605), anti-CD31 Brilliant™ Violet 605 (BV605) (BioLegend, #102427), anti-CD31 PE-Cy7, anti-CD144 APC (Thermo Fisher, #17-1441-80). Viability dyes used in flow cytometry: live/dead fixable aqua (ThermoFisher, #L34965), 7-aminoactinomycin D (7-AAD) viability solution (eBioscience, 400-6993-50). Antibodies against mouse in immunofluorescent staining: anti-CD31 (Abcam, #ab28364), anti-CD45 (BioLegend, #103101), anti-vascular endothelial (VE)-cadherin (R&D, #AF1002-SP), anti-Ng2 NG2 chondroitin sulfate proteoglycan (Millipore, #ab5320).

**Cell Lines and Cell Culture**

Human cardiac microvascular endothelial cells (HMVECs, Lonza, #CC-7030) were cultured in microvascular endothelial cell growth medium-2 (EGM-2 MV) (Lonza, #CC-3202). Human umbilical vein endothelial cells (HUVECs) were cultured in M199 medium (HyClone) supplemented with 20% fetal bovine serum (FBS; HyClone), endothelial cell growth supplement (ECGS, 50 μg/ml, BD Biosciences), heparin (50 μg/ml) and 1% penicillin, streptomycin, and amphotericin (PSA, Invitrogen). Cells were grown on 0.2% gelatin-coated flasks, plates, or dishes in a humidified incubator at 37°C with 5% CO2. All *in vitro* assays used HMVEC (purchased at P4, used at P8-9), which was justified to be more pathophysiological relevant angiogenic cell type compared to HUVEC. In 3D sprouting assay, where HMVEC had lower efficiencies in bead-coating than HUVEC, earlier passages of endothelial cell were required for the sprouting phenotype; here HUVECs at P5 were used.

**Fluorescence-Activated Cell Sorting and RNA Isolation for RNA-Seq**

To obtain CD45+CD31+ and CD45−CD31− cells from mouse hindlimb, skeletal muscle was dissociated into single-cell
suspension through the method reported previously (43). Briefly, hindlimb muscle was dissected, minced, and incubated in muscle dissociation buffer containing collagenase, type 2 (Worthington, #LS004176) and dispase II (Life Technologies, #17105-041) for 1.5 h. After washing with FACS buffer (2% FBS in PBS), cells were stained with surface antibody anti-CD45 (BioLegend, #103116) and anti-CD31 (BioLegend, #102427) for 30 min at room temperature. All cell-sorting experiments were performed using an Aria Cell Sorter (BD Biosciences) in Temple University Lewis Katz School of Medicine Flow Cytometry Core. The CD45−CD31− and CD45+CD31+ cells were sorted directly into TRIzol, and RNA was extracted using miRNeasy Mini kit (Qiagen).

Total RNA libraries were prepared by using Pico Input SMARTer Stranded Total RNA-Seq Kit (Takara). In short, 250 pg–10 ng total RNA from each sample was reverse-transcribed via random priming and reverse transcriptase. Full-length cDNA was obtained with SMART (Switching Mechanism At 5′ end of RNA Template) technology. The template-switching reaction keeps the strand orientation of the RNA. The ribosomal cDNA is hybridized to mammalian-specific R-Probes and then cleaved by ZapR. Libraries containing Illumina adapter with TruSeq HT indexes were subsequently pooled and loaded to the HiSeq 2500. Single end reads at 75 bp with 30 million reads per sample were generated for bioinformatic analysis. RNA-seq data was deposited into NCBI-GEO dataset (GSE155012).

### Protein Extraction and Western Blot Analysis
Protein extracts were collected from HMVECs or mouse hindlimb skeletal muscle. Protein concentration was determined by bicinchoninic acid (BCA) assay with BSA standards. Protein was separated on SDS-polyacrylamide gel and transferred onto nitrocellulose membranes. Membranes were blocked with 5% BSA in Tris-buffered saline containing 0.1% Tween 20 [TBS, 50 mM Tris (pH 7.5), 150 mM NaCl, and 0.1% Tween 20 (v/v)]. Membranes were incubated with primary antibodies overnight at 4°C, then washed extensively with TBS and incubated with the appropriate horseradish peroxidase-labeled secondary antibodies for 1 h at room temperature. Afterwards, membranes were incubated with enhanced chemiluminescence (ECL) substrate for horseradish peroxidase (Thermo Scientific, #34578) and the ECL intensity was detected by Fujifilm LAS-4000. The expression levels of proteins as indicated by the ECL intensity were measured with ImageJ software. The experiments with human angiogenesis protein array (R&D Systems, #ARY007) were performed following the manufacturer’s protocol.

### Enzyme-Linked Immunosorbent Assay
After euthanizing mice, plasma and skeletal muscle were collected for protein extraction. Less than 50 mg of muscle was added into molar with liquid nitrogen and ground into powder. 400–1,000 µl of lysis buffer (Cloud-Clone, #IS007) was used to extract protein. After sonication at 40 mA for 10 s intermittently and centrifugation at 10,000 g for 5 min at 4°C, supernatants were carefully collected into a new 1.5 ml tube. IL-35 protein expression in mouse plasma and muscle was measured using ELISA kit (Biomatik, #EKU05328) by following its product instruction.

### RNA Isolation and Real-Time Quantitative Reverse Transcription PCR
RNA collected from HMVECs was isolated using the miRNasy Mini Kit (Qiagen, #217004). RNA from mouse hindlimb skeletal muscle was isolated using RNeasy Fibrous Tissue Mini Kit (Qiagen, #74704). The cDNA was synthesized using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, #4368814), and qRT-PCR was performed with Taq Universal SYBR Green Supermix (Bio-Rad). Samples were amplified by 40 cycles of 5 s at 95°C and 30 s at 60°C. Results were calculated using the ΔΔ Ct method relative to the reference control gene of β-actin.

For PCR array, HMVECs were treated with 10 ng/ml of rhIL-35 for 6 h, triplicate samples were pooled to collect mRNAs, which were then converted to cDNA and assayed with the RT² First Strand Kit (Qiagen, #330401). The pooled mRNAs were used to screen for 84 EC biology-related gene expression changes following the direction of the Human Endothelial Cell Biology PCR Array (Qiagen, #330231). Data were analyzed with the SABiosciences PCR Array Data Analysis Software.

Human EB13 (ThermoFisher Scientific, #4331182) and mouse Il12a (Bio-Rad, #10025636) were detected using commercial kits. All other primers were designed and purchased from Integrated DNA Technologies. Primer sequences are listed in Table 1.

### Immunofluorescence Staining
To prepare the frozen sections, collected samples were fixed in 2% paraformaldehyde (PFA) overnight at 4°C, incubated in 15% sucrose in PBS (w/v) for 2 h, and then 30% sucrose overnight at 4°C. Gastrocnemius muscle was cut in the center and embedded with the cut surface facing down in Tissue-Plus O.C.T compound (Fisher Scientific, #23-730-571) and snap frozen on an aluminum block (pre-chilled) in liquid nitrogen. Sections of 10-μm in thickness were cut on Leica CRYOCUT 1800.

For paraffin sections, collected samples were fixed in 4% PFA overnight at 4°C, then transferred into 70% ethanol before embedding. Sections of 5-μm thickness were deparaffinized and treated with a heat-induced antigen retrieval with 1 mM EDTA-NaOH (pH 8.0) solution.

Slides were blocked in PBS with 3% BSA for 1 h at room temperature. Primary antibodies were incubated overnight at 4°C in the blocking buffer. Secondary antibodies were added into the blocking buffer and incubated for 1 h at room temperature. Excess antibodies were washed in PBS with 0.5% Tween 20. Slides were then mounted in VECTASHIELD HardSet Antifade Mounting Medium with 4′,6-diamidino-2-phenylindole (DAPI, Vector, #H-1500-10). Stained sections were imaged by a Leica TCS SP8 confocal microscope using ×10, or ×20 objectives.

### Tube Formation Assay
Reduced growth factor basement membrane matrix (Trevigen, #3433-005-R1) was coated on the 15-well µ-slides (ibidi, #81506) for 30 min. HMVECs were trypsinized, seeded on the coated
μ-sides at a density of 10,000 cells/ml in EGM-2 MV medium with or without LPC (30 μM), and incubated for 4–6 h at 37°C. Phase contrast images were taken at x6.4 magnification with or without Calcein AM (Trevigen, #4892-010-01), a viability dye. Images were analyzed using Angiogenesis Analyzer for ImageJ developed by Dr. Gilles Carpentier (http://image.bio.methods.free.fr/ImageJ/Angiogenesis-Analyzer-for-ImageJ).

### Wound Healing Migration Assay

HMVECs were seeded on 6-well tissue culture plate and cultured until 80% confluence. After starvation overnight in EBM2 plus 0.1% FBS, the monolayer of cells were scratched with 1 ml pipette tip to create an across at the center of the well. Then cells were gently washed twice with medium to remove the detached cells and replenished with fresh starvation medium containing FGF2 (80 ng/ml), with or without IL-35 (40 ng/ml). The wound healing process was monitored for approximately 12 h. Olympus microscopy IX71 was used to image the cells at the first time point T0 and the last time point T12. For data analysis, ImageJ was used to measure the wound area at T0 and T12. Migration distance = (Area(T0) − Area(T12))/(2 × Length of the field).

### 3D Sprouting Assay

Passage (P) 5 HMVECs were trypsinized and incubated with sterile Cytodex 3 microcarrier beads (GE Healthcare, #17-0485-01) at the ratio of 500 cells per bead in a sterile tube with EGM-2 medium at 37°C for 4 h. During the 4 h, the mix was gently shaken every 20 min. Then, around 250 coated beads were seeded in 0.5 ml fibrin gel (2 mg/ml fibrinogen (Sigma, #F-8630), 0.15 U/ml aprotinin (Sigma, #A-1153), and 0.625 U/ml thrombin (Sigma, #T-4648), 100 ng/ml rhVEGF-A165 (Peprotech, #100-20), 30 ng/ml rhFGF-basic (Peprotech, #100-18B), with or without 30 μM LPC (Avanti, #S5567SP) in a 24-well plate. After seeding the beads, 1 ml EGM-2 with 20,000 fibroblasts was added dropwise. Culture medium was changed every other day, and beads sprouts were counted at day 10.

### Animals

All mice used were on a C57BL/6 background. Except Supplementary Figure 2, in all the other animal experiments, male mice were used. Apolipoprotein E deficient (ApoE−/−) mice (strain name: B6.129P2-Apoetm1Unc/J), Il12rb2−/− mice (strain name: B6.129S1-I12rb2tm1JmJ) and wild type (WT) mice (strain name: C57BL/6J) were purchased from the Jackson Laboratory (Bar Harbor, ME). All mice were weaned at 3 weeks of age and maintained on chow diet. In the Matrigel plug assay experiment, severe combined immunodeficiency (SCID) (NOD.Cg-Pkdscid Il2rgtm1Wjl/Sjl) male mice at 12-week old were used and the experiment was performed with collaborator Dr. Shu Meng from Houston Methodist Hospital; female mice did not response to angiogenic stimuli very well, thus not ideal for this experiment model. In bone marrow transplantation experiment, CD45.1 WT (strain name: B6.12SJ-Tptrca Pepcb/Boyj) mice were used as the recipient and enhanced green fluorescent protein (EGFP) (strain name: C57BL/6-Tg(CAG-EGFP)131Osb/LeySopJ) male mice were used as the donor. In cytokine injection therapy experiment, both male and female mice were used. All animal experiments were performed in accordance with the Institutional Animal Care and Use Committee (IACUC) Guidelines and Authorization for the use of Laboratory Animals and were approved by the IACUC of Temple University Lewis Katz School of Medicine and Houston Methodist Hospital.

### Mouse Genotype

Mouse genotypes were confirmed with PCR followed by agarose gel separation. Extracta DNA Prep for PCR (Quanta, #95091) was used to extract DNA from mouse toe. Briefly, mouse tissue was digested with 50 μl of extraction reagent at 98°C for 30 min, and then added 50 μl of stabilization buffer and stored at 4°C.

IL-12RB2 genes were amplified with primers for the mutant gene (5′-CACGGTGTAAGCAAGCTAGCTG-3′ and 5′-GCCCTGAATGAACTGCAGG-3′) and the WT gene (5′-GTTGGTAAGCAGCTAGCTG-3′ and 5′-GGCTGGTATTCCCAAGCG-3′). The PCR cycle for IL-12RB2 was 94°C for 3 min, 35 cycles of 94°C for 30 s, 72°C for 1 min, 66.8°C for 1 min, and 72°C for 2 min.

ApoE genes were amplified with 3 primers (5′-GGGAGAACGCAGG-3′, 5′-TGTGACTTGGGAAGGTCTG-3′, and 5′-GCCGCCCGACTGATC-3′). And the

| TABLE 1 | Sequences of human and mouse primer pairs. |
| Species | Gene Name | Forward (from 5′ to 3′) | Reverse (from 5′ to 3′) |
|---------|-----------|-------------------------|------------------------|
| Human   | ACTB      | ACCTTCATCACATGAGCTGCG   | CTCGQATAACAGCTGACATGG  |
| Human   | IL12A     | CTCGAAGCAACCCAGAATGTTTC | ATCTCTTTGAGAAGCTGACAGG |
| Human   | IL6ST     | GCAAGTCTCTACATCCAGTACACG | TOCCACTACAGCCTTATTTTC |
| Human   | IL12RB2   | ATCTCCCTTTTGTTTTGCC     | TGAAQGAGCAGCTAGCTTTAAG |
| Mouse   | Actin     | GCCTGATTTTCCTCCTACAGT   | CGCAGTGGTAAACTGCGGGT   |
| Mouse   | Exb10     | CAAAGAAGACGCGCGAAGAGAG  | GGGTAGCTCCAAGAGCCAGAG |
| Mouse   | Il6       | AGATGAAAGTGAGAAAGATG    | GATTAAAGCAGAGAAGACAGCC |
| Mouse   | Il12rb2   | GAAGCTCTTTTACATCCTCCTG  | GATGATGAGTGGTTTGGAGAG |
| Mouse   | Col1a2    | AGAGTATCGTGGATTCCAGAG   | CAGAAAACTTCGCTGAGAG |
| Mouse   | Col11a1   | ACAACCCCCCTGATAGAAGATGGA| AGGTTTCACTCCATAACCCAG |
| Mouse   | Col18a1   | CAGACCTCTCAAGACCTGCTGG  | AGGGCACACTGATCAATGTT |
| Mouse   | Adam12    | AGAATCCCATCTCAGATTCTG   | TTCCTGGCTCTGCTGAAACG |
| Mouse   | Mipr12    | CGTCCTCTCAGTGAATGACAGT  | AGTGTGCTCTAAGCCAAAGAG |
| Mouse   | Mipr14    | GAGTCGAGACAGAGAAGCATG   | TTTTGCGCCTCATTGCGAGAAG |
| Mouse   | Mipr19    | GAAGCAGAGAAGAGAGAGAG    | AGACATAGTGTCTGCCACAG |

Frontiers in Immunology | www.frontiersin.org 5 October 2020 | Volume 11 | Article 5958135
PCR cycle for ApoE was 3 cycles of 94°C for 5 min, 60°C for 30 s, 72°C for 30 s, and 30 cycles of 94°C for 30 s, 60°C for 30 s, 30°C for 20 s, and 72°C for 7 min.

The PCR product was then mixed with DNA loading dye and separated by gel electrophoresis with a 1.5% agarose gel. The DNA sizes for IL-12RB2 are 265 bp (WT) and 500 bp (mutant), and that of ApoE are 155 bp (WT) and 245 bp (mutant).

**Hindlimb Ischemia Model**

Age-matched 10–12-week-old male or female mice were used in HLI model as reported previously (44). Under anesthesia, an incision was made in the skin at the mid-portion of the left hindlimb. The femoral artery was then dissected free from the nerves and the proximal and distal loci of the femoral artery were ligated and cut, as well as its side branches. Hindlimb blood flow was measured on postoperative days 0, 3, 7, 14, 21, and 28 using a laser Doppler imaging (LDI) blood flow analyzer (moorLDI2-IR, Moor Instrument). The penetration depth is ~5 mm when the Infra-Red laser of 785 nm is used (45). Blood flow was quantitatively assessed by the ratio of mean flow signals of the left (ischemic) to the right (non-ischemic) planter. Mice with blood flow ratio higher than 0.2 at postoperative day 0 were excluded to ensure the success of the ligation procedure, which were correlated well with that reported (46). 80–90% blood loss is typical of what we see after a femoral artery ligation procedure, which is also consistent with the application note on HLI by Moor Instrument. Calf muscles including gastrocnemius and soleus were used for most molecular experiments except flow cytometry. Due to the limited alive cell after single cell suspension, the whole limb muscle was dissected for flow cytometry.

**Matrigel Plug Assay**

Matrigel (Corning, #354234) was thawed at 4°C overnight before the experiment. SCID male mice were anesthetized and injected with Matrigel subcutaneously in the shaved abdomen region of the mice (two injections in each mouse). Each Matrigel injection contains 400 μl total volume (300 μl Matrigel + 100 μl other reagents with the final concentrations of 30 U/ml of heparin, 40 ng/ml of FGF2, and with or without 40 ng/ml of IL-35). Matrigel plugs were removed after 5 days for molecular studies.

**Cytokine Injection**

Recombinant mouse IL-35 was administered intramuscularly (i.m.) (0.3 μg/gastrocnemius (GC) muscle in 20 μl PBS) at the time of HLI procedure, and three times a week afterwards until the end of observation. The non-surgery limb and PBS control group limb were injected with 20 μl PBS as the internal and experimental control, respectively. The used dose was based on similar literatures using cytokine injection in mouse muscle (47).

**Bone Marrow Transplantation**

CD45.1 WT male mice at 5-week old were irradiated with a single dose of 8 min and 29 s in RS2000 X-ray irradiator from Radsource. Then, bone marrow cells were collected from EGFP donor mouse femurs and filtered through a 70 μM cell strainer. Each irradiated CD45.1 mouse was injected by retro-orbital with $5 \times 10^6$ donor bone marrow cells. To assess the irradiation efficacy, control mice were irradiated but did not receive donor bone marrow cells. After 6 weeks, all recipient mice survived, while the control mice were dead. Peripheral blood was assessed with flow cytometry, and more than 90% of mononuclear cells were EGFP⁺. The chimeric mice were then performed with HLI surgery and followed with IL-35 or PBS injection.

**Statistical Methods**

Data were expressed as the mean ± standard error of the mean (SEM) throughout the manuscript. For comparisons between two groups, the two-tailed Student t-test was used for evaluation. For comparisons across multiple groups, one-way ANOVA with Bonferroni post-test adjustment was used. For the blood perfusion ratio, since the longitudinal data were collected over a 4-week period on mice for the various experimental groups [e.g., 2 strains (WT vs. Il12rb2) × 2 treatments (PBS or IL35)] on both sexes, we employed the mixed-effects linear model approach to explore several potential effects of interest, including the gene effect, treatment effect, sex effect, and time effect. Estimation and testing of such effects between various groups of interest were performed using the least squares means method with the Tukey–Kramer adjustments made for multiple comparisons in the mixed-effects regression models while taking into account of the fact that multiple data points were collected on each mouse over time. Variability of the blood perfusion ratio as well as its correlation across different days were allowed to vary by the combinations of time points and groups that were being examined, which is a far better model than that being afforded by a common ANOVA model. Interaction between time and various factors of interest (e.g., strain, treatment, and sex) was always considered in the regression model. Data shown are representative of two to three independent experiments, including analysis from wound healing assay, immunofluorescent staining, flow cytometry, and western blot. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

**RESULTS**

**IL-35 and Its Receptor Subunit IL-12RB2, but Not IL-6ST, Are Induced in the Ischemic Muscle After Hind Limb Ischemia**

Previous reports showed that a special population of Treg potentiates muscle repair (48); and IL-35 is predominantly secreted by Treg (3, 13), suggesting a possibility that IL-35 may modulate hind-limb ischemia (HLI) angiogenesis related to muscle repair. We hypothesized that IL-35 signaling is induced in HLI angiogenesis model (Figure 1A). At physiological conditions, the gene expressions of IL-35 subunits (IL-12A and EBI3) are very low in the skeletal muscle, and protein levels are undetectable based on the Human Protein Atlas database (http://www.proteinatlas.org), which correlated well with our previous report (4). IL-35 signaling involved three possible formats further described in the following results (Figure 1B). To test this hypothesis, we
extracted RNAs from ischemic muscle at 0, 3, and 7 days post-ischemia (dpi). The results showed significantly increased expression of IL-35 subunit EBI3 and IL-35R subunit IL-12RB2, but reductions of IL-35 subunit IL-12A and IL-35R subunit IL-6ST (Figure 1C). The upregulation of EBI3 and downregulation of IL-12A were consistent with the results of the microarray dataset GSE3313 found in NIH Geo DataSets database (https://www.ncbi.nlm.nih.gov/gds/) (Supplementary Figure 1A), where gene expression data were also collected from the ischemic mouse muscle after HLI (49). Because IL-35 subunits are shared with other IL-12 family cytokines and the inconsistent changes of the two subunits induced by ischemia, we performed ELISA to detect the changes of IL-35 protein levels in skeletal muscle and ischemic muscle after HLI. The results showed that IL-35 was induced in ischemic muscle after HLI and peaked at 7 dpi, which was about threefold higher compared to the basal level in non-surgery mouse muscle (Figure 1D). However, its expression level was not detectable in plasma at the basal level or after HLI (Figure 1E).

To mimic the ischemic environment in vivo, human microvascular endothelial cells (HMVECs) were cultured under 0.2% O₂, where hypoxia-inducible factor 1 (HIF1A) was significantly upregulated (Supplementary Figure 1B). HIF1A upregulation indicated the establishment of hypoxic environment. The results showed that 24-h treatment of hypoxia induced the gene expressions of IL-35 cytokine subunits IL-12A and EBI3, decreased that of IL-6ST, while did not change that of IL-12RB2 in HMVECs (Supplementary Figure 1C). These results suggested that the induction of IL-35 cytokine and its receptor signaling in ischemic muscle the first 12 days after HLI and hypoxic HMVEC was of pathophysiological relevance, and IL-12RB2 was the more responsive IL-35 receptor (IL-35R) subunit than the second IL-35R subunit IL-6ST. These results suggest that IL-12RB2-IL12RB2 homodimer may be responsible for IL-35 signaling in ischemia muscle.

**Hindlimb Ischemia-Induced Angiogenesis Is Improved in IL12RB2−/− Mice, in ApoE−/−/IL12RB2−/− Mice Compared to Wild-Type Controls, and ApoE−/− Controls, Respectively, Where Hyperlipidemia Inhibits Angiogenesis In Vivo and In Vitro**

IL-35 receptor has a few functional formats (Figure 1B), which include: 1) homodimer of IL-12RB2, 2) homodimer of IL-6ST, 3) heterodimer of IL-12RB2 and IL-6ST, and 4) heterodimer of IL-12RB2, and IL-27RA (13, 14, 50). Previously we reported that IL-35 signal is abolished by either IL-12RB2 or IL-6ST inhibition in ECs (5). In our study, the induction of gene expression of IL-12RB2 and reduction of IL-6ST in the ischemic muscle (Figure 1C) suggested that IL-12RB2, potential homodimer, played an important role in regulating IL-35 signaling in HLI model. As we recently reviewed (13), IL-12RB2 is the receptor subunit shared by two IL-12 family cytokines, IL-12 (pro-inflammatory) and IL-35 (anti-inflammatory), while IL-6ST as a receptor subunit is widely shared by IL-6 family cytokines, which predominantly drive pro-inflammatory responses. Also, it has been shown that IL-12RB2 deficiency leads to spontaneous autoimmunity in aged mice (51), which indicates that IL-12RB2 is the anti-inflammatory receptor subunit driving the anti-inflammatory

![FIGURE 1](https://example.com/figure1.png)
function of IL-35 (14, 52). We hypothesized that IL12RB2 mediates IL-35 inhibition of HLI-triggered angiogenesis. To examine this hypothesis, we performed HLI procedure on IL-12RB2 deficient mice. The result showed for the first time that IL-12RB2−/− mice have significantly improved blood reperfusion in the ischemic legs compared to those of WT control mice (Figure 2A), suggesting that IL-35 inhibits HLI-induced angiogenesis via IL-12RB2-dependent manner.

One disadvantage of the HLI mouse model to study angiogenesis is that healthy young mice are always used, which
is not comparable to aging diseases like PAD (53). Hyperlipidemia is a common complication in patients with PAD. We (Figure 2B) and others (54) have seen that hyperlipidemia dampens angiogenesis in vivo. We previously reported that gene expressions of IL-35 subunits and its essential receptor subunit IL-12RB2 were induced in mouse aorta after 3-week high-fat diet in ApoE/−/− mice (9), the impaired angiogenesis may partially act through the induction of IL-35. We hypothesized that IL-35 inhibits HLI-triggered angiogenesis in the presence of hyperlipidemia. Thus, to be more clinically relevant, we also used hyperlipidemia model by crossing Il12rb2−/− mice with hyperlipidemia-conditioned apolipoprotein E deficient (ApoE−/−) mice. Consistently, ApoE/−/Il12rb2−/− showed significant improvement of blood reperfusion in the ischemic leg at 7 dpi; however, the overall rescue effect of IL-12RB2 deficiency at other time points was not significant (Figure 2B). Of note, the kinetics of the response to HLI in C57 wild-type mice and ApoE/−/− mice appeared different, suggesting that hyperlipidemia stimuli inhibit angiogenesis. To verify the effect of hyperlipidemia, two in vitro angiogenesis models including EC tube formation assay and three dimensional (3D) sprouting assay showed that 30 μM lysophosphatidylcholine (34) (LPC, a proatherogenic lipid that mimics hyperlipidemia stimuli on EC in vivo) restrained tubular network formation in HMVECs (Figures 2C, D) and the sprouting length from the 3D beads (Figures 2E, F), but not the number of sprouts per bead in HUVECs (Figure 2G). The reason that early passage of HUVEC was used in 3D sprouting assay was because HMVEC do not attach to 3D beads well nor sprout well. Our results were also well correlated with that reported by Dr. Belmadani on IL35 cytokine subunit p35 knockout mice fed with chow diet and high fat diet in 14 dpi (55). Of note, as we reviewed recently, IL35 cytokine subunit p35 is shared with IL12 (13). Taken together, these results suggest that IL-35 inhibits HLI-induced angiogenesis in the day 7 after HLI in the presence of hyperlipidemia.

**IL-35 Cytokine Injection Delays Blood Perfusion Recovery at Day 14 After Hindlimb Ischemia and Increases Gene Expression of IL-12RB2**

As we discussed earlier, IL-12RB2 is the receptor subunit shared by two IL-12 family cytokines, IL-12 and IL-35. Of note, IL-12 has been shown as an anti-angiogenic factor in both tumor (56) and myocardial infarction (57). Thus, we thought that the improvement of angiogenesis in HLI by deleting IL-12RB2 could be merely the effect of blocking IL-12 signaling rather than IL-35. To rule out the possible effect of IL-12 in HLI, we hypothesized that IL-35 cytokine injection inhibits HLI-triggered angiogenesis as the gain-of-function approach. To examine this hypothesis, we use IL-35 injection of recombinant mouse IL-35 protein directly into ischemic muscle after HLI with the method that we reported previously (9). As shown in Figure 3A, mice were administered via i.m. with IL-35 [0.3 μg/gastrocnemius (GC) muscle in 20 μl PBS] at the time of HLI procedure (47, 58, 59) and three times a week afterward until the end of the observation as we previous reported (60). The results showed that IL-35 injection inhibited blood reperfusion compared to the PBS group, especially at 14 dpi (Figure 3B). And this effect of IL-35 at least partially relied on receptor subunit IL-12RB2 (Supplementary Figure 2A), where IL-12RB2 deficiency rescued the dampened blood flow recovery by IL-35. We also found that IL-35-IL12RB2 signaling inhibited HLI-induced angiogenesis specially in male mice, and male outperforms female regardless of the treatment or genotype (Supplementary Figures 2B–F), which were consistent with previous report (61). Sex differences in vascular physiology and pathophysiology have been well accepted and should be put into consideration for the future studies.

Then, since bone marrow transplantation allows for determining the roles of bone marrow-derived cells versus tissue resident cells in modulating HLI and other vascular pathologies as we reported (62), we hypothesized that bone marrow (BM) cells promote HLI-triggered angiogenesis. To test this hypothesis, we performed BM transplantation with enhanced green fluorescence protein (Egfp)-transgenic mouse BM (BM transplantation method, Figure 3C). The results showed that IL-35-injected mouse GC muscle after HLI had much bigger avascular areas than that of the controls, judged by significant less CD31+ staining and surrounding EGFP+ BM-derived cells at 14 dpi (Figures 3D, E). However, we did not see significant changes of vascular density at the vascular area, judged by the percentage of CD31+ area in the field of view of IL-35-treated HLI mice (Figure 3F), suggesting that IL-35 inhibitory effects was focused on HLI-triggered angiogenesis. In addition, the EGFP+ BM-derived cells were in high concentration in vascular areas but not in avascular areas, suggesting that EGFP+ BM-derived cells facilitate angiogenesis in the presence of IL-35. Of note, we did not find the evidence that GFP+ BM-derived cells incorporate into CD31+ cells (not shown). This result was confirmed by another experiment with muscle samples analyzed by flow cytometry and immunofluorescent (IF) staining (Figures 3G, H), though there was a trend of decreasing EC percentage at the earlier time point (3 dpi) of HLI in the IL-35-injected group. To confirm the inhibitory role of IL-35 in angiogenesis, we performed another in vivo angiogenesis model, Matrigel plug assay, where IL-35-contained plugs showed significantly less growth of new blood vessel (Supplementary Figure 3). These results suggest that IL-35 inhibits HLI-triggered angiogenesis in the HLI-affected area of tissue but not in the HLI-non-affected areas of tissue.

We also found that IL-35 injection upregulated gene expression of IL-12RB2 but not IL-6ST in the ischemic muscle at 3 dpi (Figure 3I). The above qRT-PCR assay was performed using the whole muscle extracts, which included many cell types such as immune cells, vascular smooth muscle cells (VSMCs), and ECs. The induction of both IL-35 subunits, IL-12A and EBI3, implicated that exogenous IL-35 could stimulate these immune cells (14, 50) and/or ECs in the ischemic muscle to secrete more IL-35. In our previous findings, IL-35 can directly signal through EC and inhibit LPC- or LPS-induced EC activation (5, 8). Therefore, we treated HMVEC with IL-35 for
FIGURE 3 | IL-35 cytokine injection delays blood perfusion recovery in the ischemic leg of hindlimb ischemia (HLI) and increases gene expression of IL-12RB2.

(A) Experimental schematics. IL-35 group mice were intramuscularly (i.m.) administered with IL-35 [0.3 µg/gastrocnemius (GC) muscle in 20 µl PBS] at the time of HLI procedure and three times a week afterwards until the end of observation. The non-surgical limb was also injected with 20 µl PBS as internal control. (B) Blood perfusion ratio of IL-35- or PBS-injected WT or Il12rb2−/− mice. (C) Bone marrow transplantation experimental schematics. (D) Representative images of the whole GC muscle (left panel) and higher magnification of vascular density (right panel) in vascular area of PBS- or IL-35-injected ischemic muscle at 14 dpi. Tissues were stained with anti-CD31 (red) and DAPI. Lines, where blood vessels were rarely visible. The left two images were taken using tile scan in Leica TCS SP8 system and merged to present the whole tissue section. The avascular area was indicated with red dash at 14 dpi. (E) Statistics of the percentage of the avascular area EGFP+ indicated infiltrated bone marrow-derived cells. (F) Statistics of the percentage of CD31+ cells in the vascular area of the GC muscle at 14 dpi. (G) Statistics of percentage of CD31+ cells in CD45+ cell population in IL-35 or PBS-injected groups using flow cytometry. (H) Percentage of CD45+CD31+ ECs in IL-35 or PBS injected ischemic muscle at 3 and 14 dpi using immunofluorescent staining. (I) Normalized gene expression of IL-35 signaling complex in the ischemic muscle at 3 dpi. IL-35 group mice were i.m. injected with IL-35 at the time of HLI surgery. (J) Normalized mRNA expression levels of IL-35 receptor subunits after 6 h of 40 ng/ml of IL-35 treatment in HMVECs under normoxia or hypoxia condition. All animal results were collected from male mice. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ****p < 0.0001.
were increased at 1, 7, and 14 dpi and were peaked at 7 dpi (39), suggesting that after 7 dpi, pro-inflammatory mechanisms are decreased and anti-inflammatory mechanisms play more significant roles than pro-inflammatory mechanisms. We found that IL-35 did not significantly inhibit the regenerative angiogenesis in the late phase of hindlimb ischemia-triggered angiogenesis in 21 and 28 dpi (Figure 3B), which were well correlated with our other two results that first, IL35 cytokine levels were increased at 1, 7, and 14 dpi and were peaked at 7 dpi (Figure 1D); second, the deficiency of IL12RB2 in ApoE−/− background did not significantly improve angiogenesis at 21 and 28 dpi (Figure 2B); on those two time points the blood perfusion in the deficiency of IL12RB2 had no differences with that of ApoE−/− single gene knockout controls. Of note, one of the discrepancies was that IL12RB2−/− mice have significantly improved blood reperfusion in the ischemic legs at all the time points compared to those of WT control mice (Figure 2A), which may result from the fact that IL-12RB2 is the receptor subunit shared by two IL-12 family cytokines, IL-12 and IL-35; and IL-12 may inhibit regenerative angiogenesis. A previous report showed that at 21 dpi, HLI-induced muscle injury is almost fully recovered as judged by the expressions of 18 chemokines and receptors, 23 cytokines and receptors, 26 energy metabolism regulators and histological recovery of muscles (63). The findings suggested that starting from 14 dpi, HLI-triggered muscle injury experiences regenerative angiogenesis and muscle repair, which continues to 28 dpi. Therefore, taken together, our new findings suggest that IL-35 inhibits HLI-triggered inflammatory angiogenesis at the early phase and spare regenerative angiogenesis at the late phase of HLI recovery.

Transcriptome Analysis of Endothelial Cells at 14 Days Post-Ischemia Reveals a Disturbed Extracellular Matrix Remodeling in IL-35-Injected Mice

We hypothesized that IL-35 regulates angiogenesis via modulating the transcriptome of EC in the muscle after HLI. To examine this hypothesis, we specifically isolated CD45−CD31+ bona fide EC from the ischemic muscle (Figure 4A) at 0, and 14 dpi using fluorescence-activated cell sorting (FACS). About 0.1 million ECs were collected for RNA extraction and deep-sequencing. A comparison of EC RNA-Seq data (transcriptome) of IL-35 injection and PBS control was made at 14 dpi since our data presented above showed that IL-35 inhibits angiogenesis at 14 dpi (Figure 3B). Consistent with the Laser Doppler result that the blood flow of PBS-injected group recovered about 80% of that of non-ischemic leg at 14 dpi, we found this group had a very similar transcriptomic pattern compared to the control group (without HLI surgery). However, the IL-35-injected group showed a quite different gene expression profile. With the significance criteria of false discovery rate (FDR) <0.05, [fold change (FC)] >1.5 and Max [fragments per kilobase of exon model per million reads mapped (FPKM)] >5, there were 341 differentially expressed genes (DEGs) in IL-35-injected ECs (Figure 4B). Gene set enrichment analysis (GSEA) (https://www.gsea-msigdb.org/gsea/index.jsp) revealed several significant enriched gene sets regulating ECM remodeling, including molecular pathways of collagen, and integrin β1 and β3 (Figure 4C).

This enrichment gene set profile is likely due to the IL-35-upregulated genes in the collagen family (eight genes including types I, V, VI, VIII, XII, XIV, and XVIII), matrix metalloproteinase (MMP) family (three genes including Mmp12, Mmp14, and Mmp19), and integrin molecules (three genes including Itgb2, Itgb3, and Itga11). Representative gene expression changes were listed in Figure 4D. Due to the limited cell numbers of CD45−CD31+ endothelial cells sorted from ischemic muscle at 14 dpi, we did qRT-PCR on RNAs collected from whole ischemic muscles instead to verify the gene expression changes. The tested genes did show an upregulation trend at 14 dpi, but not at 3 dpi (Figure 5A). We also saw the increasing trend of collagen deposition in ischemic gastrocnemius (GC) muscle at 14 dpi (Figure 5B), which was consistent with the recently reported observations of IL-35 in myocardial infarction (64). Moreover, to consolidate the finding, additional collagen gene expressions were analyzed. The expression changes of eight out of 47 collagen-related genes (Supplementary Figure 4) were significantly upregulated in our CD45−CD31+ mouse endothelial cells from IL-35-treated mice in comparison to that of non-treated control mice (Figure 4D), which suggests that IL-35 may increase collagen deposition by upregulating collagen-related gene expression. The proper angiogenic process in which new blood vessels sprout from existing ones largely relies on timely regulation of ECM degradation and synthesis. These over-activated ECM remodeling genes by IL-35 at 14 dpi of HLI indicated the inhibited angiogenesis in the early stage and therefore delayed vascular/tissue repair.

IL-35 Downregulates Three Reactive Oxygen Species (ROS) Promoters and Upregulates One ROS Attenuator, Which May Functionally Mediate IL-35 Upregulation of Anti-Angiogenic Extracellular Matrix Proteins in ECs

Dr. Kevil’s team reported that sodium nitrite significantly restores ischemic tissue perfusion by 3 dpi, which returned to normal by 7 dpi (65). In addition, Dr. Belmadani’s team reported that nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (Nox4) is significantly increased in ischemic muscle in HLI (55). These reports demonstrated that ROS and RNS play a significant role in modulating the pathophysiological processes of HLI. Recently, we reported that IL-35 inhibits human aortic
EC activation via suppressing ROS generation (8, 9), mitogen-activated protein kinase pathway (5), epigenetic (9) and gene transcription (8). Of note, our experimental data have demonstrated for the first time that IL-35 not only suppresses inflammation but also inhibits ROS-mediated processes. To further demonstrate that ROS play significant roles in modulating HLI-triggered inflammation and regeneration, we examined the 165 ROS regulators, a comprehensive list, in the

**FIGURE 4** | Transcriptome analysis of endothelial cells (ECs) at 14 days post-ischemia (dpi) reveals a disturbed extracellular matrix (ECM) reorganization in the IL-35-injected mice. (A) Flow cytometry cell sorting strategy. Hindlimb muscle from control (Ctrl, without surgery) or ischemic mouse (PBS and IL-35 groups) at 14 dpi was dissected and digested for single cell suspension. Cells were stained with the surface markers of CD31 BV605 and CD45 APC-Cy7 and sorted by Aria Cell Sorter (BD Biosciences). 1 × 10^5 cells of ECs from each sample were collected for RNA extraction and deep-sequencing. (B) Heatmap of the differentially expressed genes (DEGs) in ECs of IL-35- or PBS-injected, and control groups. With the criteria of false discovery rate (FDR) < 0.05, |FC| > 1.5, and max (fragments per kilobase of transcript per million mapped reads, FPKM) > 5, we got 341 DEGs. The green-red color key was scaled based on the z-score of FPKM within the row. (C) Gene set enrichment analysis (GSEA) of the gene expression changes of ECs in IL-35-injected mouse compared to that of PBS group. Four of the most enriched pathways were presented. (D) Representative gene expression changes in different categories of ECM proteins. All results were collected from male mice. n = 3.
GSEA database in the time course, 1, 7, and 14 dpi by using the wild-type male mouse microarray datasets GSE3313 in the NIH GEO database (https://www.ncbi.nlm.nih.gov/gds/) (49). As shown in Supplementary Figure 5, the expressions of 116 out of 165 ROS regulators (70.3%) were significantly modulated in the different time courses after HLI, suggesting that ROS regulators play significant roles in modulating inflammatory angiogenesis, which we can classify into two groups for the
first time, the early phase inflammatory angiogenesis ROS regulators and the late phase regenerative angiogenesis ROS regulators. It has been reported that hypoxia triggers reactive oxygen species (ROS)-mediated inflammatory cell recruitment, migration and inflammation (66, 67), which may be the dominant feature in the early phase in HLI. Our previous report showed that IL-35 inhibits mitochondrial ROS-mediated HAEC activation and atherosclerosis. In the regenerative phase, as blood supply restores, hypoxia-triggered inflammation is decreased. Tissue remodeling and regeneration become the dominant feature. The mild hypoxia promotes survival and proliferation even in the absence of mitochondrial form of manganese superoxide dismutase (SOD2) (68, 69). As we reviewed recently (13), IL-35 promotes Treg generation, and Treg facilitates tissue remodeling and regeneration (70). Future work is needed to characterize the detailed molecular mechanisms and features of these newly proposed two phases of HLI. Taken together, our results and analysis suggest that oxygen tension and ROS (71) within the muscle may orchestrate the dominant events and transition of the two phases of HLI.

To determine whether ROS inhibition serves as a novel mechanism underlying IL-35 modulation of angiogenesis, we hypothesized that IL-35 inhibition of ROS may mediate IL-35 upregulation of anti-angiogenic extracellular matrix proteins discussed above (Figure 6A). To test this hypothesis, we first determined whether IL-35 inhibits some ROS-promoting genes and upregulates ROS-attenuating genes. As shown in Figure 6B, the expressions of 165 ROS regulator genes in the GSEA database were examined in the RNA-Seq data of IL-35-treated mouse CD45^−CD31^+ ECs in comparison to that of PBS treated mouse ECs. We found that IL-35 significantly downregulates the expressions of three ROS promoters including DNA damage inducible transcript 4 (Ddit4, REDD1, or HIF-1 responsive RTP801), tumor necrosis factor-α (TNF), and xanthine dehydrogenase (Xdh, XOR) and upregulates ROS inhibitor fibulin-5 (Fbln5), which were well correlated with IL-35 suppression of ROS in ECs as we reported (8, 9). We noticed that IL-35 inhibited ROS promoters DDIT4 and XDH were in the inflammatory angiogenesis ROS promoter group (Supplementary Figure 5), suggesting that IL-35 inhibits

![Figure 6](https://example.com/fig6.png)

**FIGURE 6** | IL-35 inhibits the expression of reactive oxygen species (ROS) regulators including downregulation of ROS promoters such as Ddit4, TNF and Xdh and upregulation of ROS attenuator fibulin-5 (Fbln5), which are connected to downstream extracellular matrix proteins, revealed by Cytoscape analysis. (A) A schematic presentation of IL-35 inhibition of reactive oxygen species generation and IL-35 upregulation of anti-angiogenic extracellular matrix proteins. Of note, we have two publications that clearly indicate IL-35 inhibition of ROS generation (the PMIDs included). (B) Our RNA-Seq data analysis indicated that IL-35 downregulates three ROS promoter genes including DNA damage inducible transcript 4 (Ddit4, REDD1, HIF-1 responsive RTP801), tumor necrosis factor-α (TNF), and xanthine dehydrogenase (Xdh, XOR) and upregulates ROS inhibitor fibulin-5 (Fbln5) in CD45^−CD31^+ endothelial cells (EC) treated with IL-35 versus PBS-treated controls with the criteria of false discovery rate (FDR) < 0.05. The regulatory functions of these four ROS regulators were reported and the PMIDs were included. Of note, the expression of 165 ROS regulators were examined in the Gene Set Enrichment Analysis (GSEA, https://www.gsea-msigdb.org/gsea/msigdb/cards/GO_REACTIVE_OXYGEN_SPECIES_METABOLIC_PROCESS). (C) The network data integration database Cytoscape analysis (https://cytoscape.org/) was used to analyze the network connection between ROS regulators and anti-angiogenic extracellular matrix proteins. The small dots were the ROS regulator genes and extracellular matrix genes that IL-35 regulated. The large dots were extracellular matrix protein pathways. The bright words, but not dim words, indicated the significance of the pathways.
inflammatory angiogenesis ROS promoters at early phase. We also noticed that IL-35 upregulated ROS inhibitor Fbhn5 was in the late regenerative angiogenesis ROS regulator group (Supplementary Figure 5). Of note, the functions of these four ROS regulators have been reported as the PMIDs shown in Figure 6B.

We then hypothesized that these four ROS regulators are functionally connected to IL-35 upregulation of anti-angiogenic extracellular matrix proteins revealed by our RNA-Seq. To test this hypothesis, we used the Cytoscape network integration database. As shown in Figure 6C, four ROS regulators (small dots) were functionally connected to extracellular matrix proteins (also small dots) via ECM pathway network (large dots). Since we previously demonstrated in the extensive experiments that IL-35 inhibits ROS generation, and that these four ROS regulators have been experimentally verified in the literature (Figure 6B), taken together, these results suggest that IL-35 inhibition of ROS generation may mediate IL-35 upregulation of anti-angiogenic ECM.

**IL-35 Inhibits Human Microvascular EC Migration and Tube Formation In Vitro Mainly Through Upregulating Anti-Angiogenic Extracellular Matrix-Remodeling Proteins**

We hypothesized that IL-35 upregulates anti-angiogenic ECM proteins not only in transcription levels but also in protein expression. To demonstrate the direct function of IL-35 to HMVECs during the angiogenic process, we performed two in vitro assays, tube formation and wound healing (Figures 6A, B). Under angiogenic stimuli of fibroblast growth factor 2 (FGF2) (72), IL-35 significantly reduced HMVEC migration (Figures 7A, B). Though IL-35 did not inhibit HMVEC migration in the

**FIGURE 7** IL-35 inhibits human microvascular endothelial cell (HMVEC) migration and tube formation in vitro mainly through upregulating anti-angiogenic extracellular matrix-remodeling proteins. (A, B) Representative images and statistics of wound healing assay. Scale bar is 500 µm Migration distance (mm) = (d₀ – dₜ)/2. After starvation with 0.1% FBS overnight, the monolayers of HMVECs were scratched and treated with/without 40 ng/ml of IL-35, 80 ng/ml of FGF2, or both IL-35 and FGF2 for 12 h. Images were taken at 0 and 12 h. Two individual experiments were combined in (B). (C, D) Representative images and statistics of tube formation assay. Scale bar is 200 µm. After starvation with 0.1% FBS overnight, HMVECs were seeded on basement membrane extract (BME) and treated with/without 10 ng/ml of IL-35, or complete culture medium for 5 h. Total master segment length was measured using ImageJ Angiogenesis Analyzer. Two individual experiments were combined in (D). (E) Three blots of human angiogenesis protein array. After starvation with 0.1% FBS overnight, HMVECs were treated with/without 80 ng/ml of FGF2, or both 40 ng/ml of IL-35 and FGF2 for 12 h. Proteins were collected and pooled from three biological replicates in each treatment, then performed proteome profile following the instruction of human angiogenesis array kit. One-way ANOVA with Bonferroni post-test adjustment was used based on two technical replicates of each protein. IL-35-changed proteins under FGF2 treatment were color-labeled and framed. (F) Normalized expression of IL-35-changed angiogenic proteins compared to FGF2-treated group. Data from (B, D) are presented as mean ± SEM. *p < 0.05; ***p < 0.001. Data from (F) has no error bar or statistics because each group only has one pooled sample for the protein array.
FIRST, common complications such as atherosclerosis and angiogenesis (44). However, there are several limitations. In most cases young mice are used for experiments and are not comparable to aging diseases (53). Second, surgical ligation in HLI model causes an acute ischemia rather than a chronic process of vascular narrowing seen in patients (77–79). Diabetic mice have been shown to present impaired angiogenesis and recovery from HLI. IL-35 has been reported to inhibit diabetic neuropathic pain (80). Due to the limited scope of this study, we were unable to include diabetic conditions into our consideration (64). Future work is needed to determine the roles of IL-35 in suppressing diabetic inflammation and modulating diabetes-impaired angiogenesis. Third, there are variabilities in the angiogenic processes in different mouse strains (78). Fourth, we acknowledge that current one stage HLI model (81) would not allow us to examine the regenerative angiogenesis in details. Thus, anti-inflammatory treatment has been presumed a promising therapy to control the local inflammation and promote desired neovascularization. TGF-β, IL-10, and newly discovered cytokine IL-35 are three primary anti-inflammatory cytokines secreted by Tregs, which are the critical immunosuppressive cells in our body (13, 26, 82, 83). TGF-β is a multifunctional regulator constitutively expressed in many tissues (4), while IL-10 and IL-35 are inflammation-induced anti-inflammatory cytokines (4). This suggests that IL-10 and IL-35 could be better therapeutic targets in the treatment of chronic inflammatory diseases. Emerging studies have shown that IL-35 is a more potent anti-inflammatory cytokine in promoting inducible Treg (50) and Breg (14) than TGF-β and IL-10. In addition, human Tregs express and require IL-35 for maximal suppressive function, and activated human Tregs have substantially upregulated gene expression of EBI3 and IL-12A, but not IL-10 or TGF-β (84). While TGF-β and IL-10 have been extensively studied, the role of IL-35 in angiogenesis has not been thoroughly investigated. It has been shown that IL-35 is expressed in many tumor cell lines compared to normal cell lines and promotes tumor angiogenesis and progression (24, 25). However, one study finds that IL-35 over-expression inhibits tumor angiogenesis through increasing apoptosis sensitivity and inhibition of proliferation in human cancer cells (27). In rheumatoid arthritis (28), it has been demonstrated that IL-35 inhibits angiogenesis. However, the roles of IL-35 in modulating angiogenesis triggered by HLI remained unknown. Our results showed that IL-35 therapy delayed inflammatory angiogenesis phase but did not make a significant difference at regenerative angiogenesis phase, suggesting that IL-35 therapy made a catch-up in facilitating the regenerative phase. Future work is required to determine the molecular and cellular mechanisms underlying the catch-up and facilitation, which were well correlated with IL-35 promotion of macrophage survival and improvement of wound healing after myocardial infarction (85). In addition, differences between the IL-35 roles in angiogenesis in HLI and myocardial infarction may also result from potential functions of cardiokines (86) and myokines (87).

To fill this important knowledge gap, we examined this issue by using loss-of-function, gain-of-function, omics data analysis, RNA-Seq, in vivo and in vitro experiments, and we have made the following significant findings: i) IL-35 and its receptor subunit IL-12RB2, but not IL-6ST, are induced in the ischemic...
muscle after HLI; ii) HLI-induced angiogenesis is improved in IL12RB2−/− mice, in ApoE−/−/IL12RB2−/− mice compared to WT and ApoE−/− controls, respectively, where hyperlipidemia inhibits angiogenesis in vivo and in vitro; iii) IL-35 cytokine injection delays blood perfusion recovery at day 14 after HLI; iv) IL-35 spares regenerative angiogenesis at the late phase of HLI recovery after 14 dpi; v) Transcriptome analysis of ECs at 14 days post-HLI reveals a disturbed extracellular matrix re-organization in IL-35-injected mice; vi) IL-35 downregulates three reactive oxygen species (ROS) promoters and upregulates one ROS attenuator, which may functionally mediate IL-35 upregulation of anti-angiogenic extracellular matrix proteins in ECs; and vii) IL-35 inhibits human microvascular EC migration and tube formation in vitro mainly through upregulating anti-angiogenic extracellular matrix-remodeling proteins. In our study, we find that IL-35 inhibits ischemia/hypoxia-induced angiogenesis but spare regenerative angiogenesis. In summary, IL-35 regulates angiogenesis in a context-dependent manner, which is similar to the function of TGF-β and IL-10. This phenomenon may explain some unsatisfied outcome of CANTOS clinical trial.

The proper angiogenic process in which new blood vessels sprout from existing ones largely relies on timely regulation of ECM degradation and synthesis. Our results of GSEA of DEGs in the IL-35-injected mouse EC at 14 days post-HLI surgery based on the data presented in Figure 2B show that in IL-35-injected mouse EC in vivo, inhibits HUVEC migration in an integrin β1-dependent manner (76). It shows that the type-1 repeat (TSR) domain in THBS-1 can bind to β1 integrins and inhibit EC migration. Thus, we propose that IL-35-enhanced integrin-mediated cell–ECM adhesion may lead to the disassembling (VE-cadherin)–plakoglobin–(α-catenin) complex, which impairs vascular AJ and EC migration. However, further experiment should be set up to test this hypothesis.

Based on our and others’ findings, we propose a novel working model (Figure 8): first, HLI triggered angiogenesis can be classified into two phases: 1) we define early phase as before the day 14 after HLI surgery based on the data presented in Figure 2B. We observed a significant improvement of blood supply in ApoE−−/−/ IL-12RB2−/− mice in the day 14 after surgery comparing to that at the day 7 after surgery but no significant differences between ApoE KO and ApoE−−/−/IL-12RB2−/− mice. 2) We observed that in Figure 3B, two curves converged at day 28 after
surgery, which indicates that IL-35-treated group has at least two phases of the effect on the hypoxia phase and recovery phase after HLI. HLI-created hypoxia triggers inflammatory angiogenesis at early phase 1 to 14 dpi as judged by upregulating 18 chemokines and receptors, 23 cytokines, and receptors. We previously reported a list of 14 proangiogenic cytokines and chemokines (38). These proangiogenic cytokines/chemokines were upregulated at the early phase of HLI (unpublished). Second, HLI induces upregulation of anti-inflammatory cytokine IL-35, which inhibits inflammatory angiogenesis by downregulating ROS regulators DDIT4 and XDH and upregulating anti-angiogenic ECM mechanisms up to 14 dpi. Third, after 14 dpi hypoxia gradually changes to normoxia at the late phase and regenerative angiogenesis as judged by upregulating energy metabolism regulators, vessel remodeling to high efficiency, and blood perfusion restored back to normal; fourth, out of 165 ROS regulators in the GSEA database, the expressions of 116 ROS regulators are significantly modulated in HLI, which can be classified into the early phase inflammatory angiogenesis ROS regulators (25 regulators upregulated at 3 dpi) and late phase regenerative angiogenesis ROS regulators (56 regulators upregulated at 7 dpi) (Supplementary Figure 5). IL-35 spares regenerative angiogenesis after 14 dpi in HLI by anti-ROS regulator Fbln5, which are well correlated with recent reports that IL-35 is protective in myocardial infarction-induced injury (85, 101). Of note, the stronger protection of IL-35 in the cardiac muscle than in the skeletal muscle may be due to tissue specificity. In addition, differences between the IL-35 roles in angiogenesis in HLI and myocardial infarction may also result from potential functions of cardiokines (86) and myokines (87). These findings provide a novel insight on the future therapeutic potential of IL-35 in suppressing ischemia/inflammation-triggered inflammatory angiogenesis at the early phase but sparing regenerative angiogenesis at the late phase, which is similar to our recent

FIGURE 8 | A new working model: Hypoxia-induced anti-inflammatory cytokine IL-35 inhibits hindlimb ischemia-triggered inflammatory angiogenesis at early phase, but spare regenerative angiogenesis at late phase.
report that IL-35 inhibits human aortic endothelial cell activation triggered by proatherogenic lipids but spare trained immunity pathway (8).

DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT
The animal study was reviewed and approved by Temple University.

AUTHOR CONTRIBUTIONS
HF carried out the experiments, data gathering and data analysis and prepared tables and figures. YSu, YSh, JSa, RC, LL, CD, CJ, KK, YL, XL, SM, EX, JT, NJ, DY, YZ, KB, JY, TR, WH, NS, JSu, XQ, XJ, and HW aided with analysis of the data. XY supervised the experimental design, data analysis, and manuscript writing. All authors contributed to the article and approved the submitted version.

FUNDING
This work was funded by the National Institutes of Health Grants to XY and HW.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.595813/full#supplementary-material

REFERENCES
1. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res (2015) 116:1509–26. doi: 10.1161/CIRCRESAHA.116.303849
2. Brenes RA, Jadowicz CC, Bear M, Hashim P, Protack CD, Li X, et al. Toward a mouse model of hind limb ischemia to test therapeutic angiogenesis. J Vasc Surg (2012) 56:1669–79; discussion 1679. doi: 10.1016/j.jvs.2012.04.067
3. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 450:566–9. doi: 10.1038/nature06306
4. Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, et al. IL-35 is a novel responsive anti-inflammatory cytokine—a new system of categorizing anti-inflammatory cytokines. PLoS One (2012) 7:e33628. doi: 10.1371/journal.pone.0033628
5. Sha X, Meng S, Li X, Xi H, Maddaloni M, Pascual DW, et al. Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing MAPK-AP-1 Pathway. J Biol Chem (2015) 290:19307–18. doi: 10.1074/jbc.M115.663286
6. Li YF, Li RS, Samuel SB, Cueto R, Li XY, Wang H, et al. Lysophospholipids and their G protein-coupled receptors in atherosclerosis. Front Biosci (Landmark Ed.) (2016) 21:70–88. doi: 10.2741/4377
7. Shao Y, Nanayakkara G, Cheng J, Cueto R, Yang WY, Park JY, et al. Lysophospholipids and Their Receptors Serve as Conditional DAMPs and DAMP Receptors in Tissue Oxidative and Inflammatory Injury. Antioxid Redox Signal (2017) 28(10):973–86. doi: 10.1089/ars.2017.7069
8. Li X, Fang P, Sun Y, Shao Y, Yang WY, Jiang X, et al. Anti-inflammatory cytokines IL-35 and IL-10 block atherogenic lysophosphatidylcholine-induced, mitochondrial ROS-mediated innate immune activation, but...
Fu et al. IL-35 Delays Hindlimb Ischemia-Induced Angiogenesis

28. Iwamoto DV, Calderwood DA. Regulation of integrin-mediated adhesions. *Curr Opin Cell Biol* (2015) 36:361–7. doi: 10.1016/j.cceb.2015.06.009

29. Hynes RO, Naba A. Overview of the matrisome—an inventory of extracellular matrix constituents and functions. *Cold Spring Harbor Perspect Biol* (2012) 4:a004903. doi: 10.1101/cshperspect.a004903

30. Aldosari S, Awad M, Harrington EO, Sellke FW, Abid MR. Subcellular Reactive Oxygen Species (ROS) in Cardiovascular Pathophysiology. *Antioxid (Basel)* (2018) 7(1):14. doi: 10.3390/antiox7010014

31. Huang Q, Zhou H, Zhang H, Huang Y, Hinojosa-Kirschbaum F, Fan P, et al. Thioredoxin-2 inhibits mitochondrial reactive oxygen species generation and apoptosis stress kinase-1 activity to maintain cardiac function. *Circulation* (2015) 131:1082–97. doi: 10.1161/CIRCULATIONAHA.114.012725

32. Li X, Fang P, Li Y, Kuo Y-M, Andrews AJ, Nanayakkara G, et al. Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation Highlights. *Arterioscler Thromb Vasc Biol* (2016) 36:1090–100. doi: 10.1161/ATVBAHA.115.306964

33. Li X, Fang P, Yang WY, Chan K, Lavallee M, Xu K, et al. uncoupled from ATP synthesis, determine endothelial activation for both physiological recruitment of patrolling cells and pathological recruitment of inflammatory cells. *Caj Physiol Pharmacol* (2017) 95:247–52. doi: 10.1113/cjpp-2016-0515

34. Chen J, Nanayakkara G, Yang WY, et al. Mitochondrial Proton Leak Plays a Critical Role in Pathogenesis of Cardiovascular Diseases. *Adv Exp Med Biol* (2017) 982:359–70. doi: 10.1007/978-3-319-55330-6_20

35. Nanayakkara GK, Wang H, Yang X. Proton leak regulates mitochondrial reactive oxygen species generation in endothelial cell activation and inflammation - A novel concept. *Arch Biochem Biophys* (2019) 662:68–74. doi: 10.1016/j.abb.2018.12.002

36. Fu H, Vadala N, Xue ER, Johnson C, Wang L, Yang WY, et al. Thrombus leukocytes exhibit more endothelial cell-specific angiogenic markers than peripheral blood leukocytes do in acute coronary syndrome patients, suggesting a possibility of trans-differentiation: a comprehensive database mining study. *J Hematol Oncol* (2017) 10:74. doi: 10.1186/s13045-017-0440-0

37. Lopez-Pastrana J, Ferrer LM, Li YF, Xiong X, Xi H, Cueto R, et al. Inhibition of Caspase-1 Activation in Endothelial Cells Improves Angiogenesis: A NOVEL THERAPEUTIC POTENTIAL FOR ISCHEMIA. *J Biol Chem* (2015) 290:17485–94. doi: 10.1074/jbc.M114.641191

38. Yin Y, Pastrana JL, Li Y, Huang X, Mallilankaraman K, Choi ET, et al. Inflammamasomes: sensors of metabolic stresses for vascular inflammation. *Front Biosci (Landmark Ed)* (2016) 117:1321

39. Limbourg A, Korff T, Napp LC, Schaper W, Drexler H, Limbourg FP. Characterization of the interactions of alpha-catenin with alpha-actinin and beta-catenin/plakoglobin. *J Cell Sci* (1997) 110(Pt 8):1013–22.

40. Gavard J. Endothelial permeability and VE-cadherin: a wacky comradeship. *Cell Adh Migr* (2014) 8:158–64. doi: 10.4161/cam.29026

41. Liu L, Cheung TH, Charville GW, Rando TA. Isolation of skeletal muscle stem cells by fluorescence-activated cell sorting. *Nat Protoc* (2015) 10:1612–24. doi: 10.1038/nprot.2015.110

42. Limbourg A, Korff T, Napp LC, Schaper W, Drexler H, Limbourg FP. Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. *Nat Protoc* (2009) 4:1737. doi: 10.1038/nprot.2009.185

43. Hayat M. Cancer Imaging: Lung and Breast Carcinomas. Elsevier Academic Press (2008).

44. Shireman PK, Quinones MP. Differential necrosis despite similar perfusion in mouse strains after ischemia. *J Surg Res* (2005) 129:242–50. doi: 10.1016/j.jss.2005.06.013

45. Kuswanto W, Burzyn D, Panduro M, Wang KK, Jang YC, Wagers AJ, et al. Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory T cells. *Immunity* (2016) 44:355–67. doi: 10.1016/j.immuni.2015.05.034

46. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A special population of regulatory T cells potentiates muscle repair. *Cell* (2013) 155:1282–95. doi: 10.1016/j.cell.2013.07.008

47. Schieckeofer, S Galasso, G Sato, K Kraus BJ, Walsh K. Impaired revascularization in a mouse model of type 2 diabetes is associated with
dysregulation of a complex angiogenic-regulatory network. *Arterioscler
Thromb Vasc Biol* (2005) 25:1603–9. doi: 10.1161/01.ATV.0000180054

50. Collender LW, Delgoffe GM, Guy CS, Vignalli KM, Chaturvedi V, Fairweather D, et al. The composition and signaling of the IL-35 receptor are unconventional. *Nat Immunol* (2012) 13:2390–9. doi: 10.1038/NN1.2943.3188

51. Airoldi I, Di Carlo E, Cocco C, Sorrentino C, Fais F, Cilli M, et al. Lack of Il11r2b signaling predisposes to spontaneous autoimmunity and malignancy. *Blood* (2005) 106:3846–53. doi: 10.1016/j.apith.2017.07.021

52. Dambuza IM, He C, Choi JK, Yu CR, Wang R, Maturapallil MJ, et al. IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease. *Nat Commun* (2017) 8:719. doi: 10.1038/s41467-017-00838-4

53. Simons M, Altalbo K, Annex BH, Augustin HG, Beam C, Berk BC, et al. State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization: A Scientific Statement From the American Heart *Circ Res* (2015) 116:69–132. doi: 10.1161/RES0000000000054

54. Couffinhal T, Silver M, Kearney M, Sullivan A, Wittenbichler B, Magner M, et al. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE−/− mice. *Circulation* (1999) 99:3188–98. doi: 10.1161/01.CIR.99.24.3188

55. Ali M, Mali V, Haddox S, AbdelGhany SM, El-Deek SEM, Abulfadl A, Matrougui K and Belmadani S. Essential Role of IL-12 in Angiogenesis in *Am J Pathol* (2017) 187:2590–601. doi: 10.1016/j.ajpath.2017.07.021

56. Airoldi I, Di Carlo E, Cocco C, Taverniti G, D’Antuono T, Ongio E, et al. Endogenous IL-12 triggers an angiogenic program in melanoma cells. *Proc Natl Acad Sci U S A* (2007) 104:3996–4001. doi: 10.1073/pnas.0609281104

57. Kan X, Wu Y, Ma Y, Zhang C, Li P, Wu L, et al. Efficiency of IL-12p35 improves cardiac repair after myocardial infarction by promoting angiogenesis. *Cardiovasc Res* (2016) 109:249–59. doi: 10.1093/cvr/crv255

58. Howard M, Muchamuel T, Andrade S and Menon S. Interleukin 10 protects mice from lethal endotoxemia. *J Exp Med* (1993) 177:1205–8. doi: 10.1084/jem.177.4.1205

59. Singh K, Kadesjö E, Lindroos J, Hjort M, Lundberg M, Espes D, et al. and Yang X-f. Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin limitation of current pre-clinical models of peripheral artery disease. *Circ Res* (2015) 101:948. doi: 10.1161/CIRCRESAHA.115.303565

60. Sha X, Meng S, Li X, Xi H, Maddaloni M, Pascual DW, et al. and Yang X-f. Metabolism-epithelium-derived factor: a potent inhibitor of angiogenesis. *Science* (1999) 285:245–8. doi: 10.1126/science.84.1158-00193-19136-6

61. Qin L, Zhang M. Maspin regulates endothelial cell adhesion and migration through an integrin signaling pathway. *J Biol Chem* (2010) 285:32360–9. doi: 10.1074/jbc.M110.131045

62. Zhang R, Saredy J, Shao Y, Yao T, Liu L, Saouaf F, et al. End-stage renal disease is different from chronic kidney disease in upregulating ROS-modulated proinflammatory secretome in PBMCs - A novel multiple-hit model for disease progression. *Redox Biol* (2020) 34:101460. doi: 10.1016/j.redox.2020.1001700014. doi: 10.1038/nprot.2009.185

63. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter B. Inhibition of endothelial cell migration by thrombospondin-1 type 1 repeats is mediated by beta1 integrins. *J Cell Biol* (2005) 168:643–53. doi: 10.1083/jcb.20040760

64. Sorrentino S, Iaconetti C, De Rosa S, Polimeni A, Sabatino J, Gareci C, et al. Hindlimb Ischaemia Impairs Endothelial Recovery and Increases Neointimal Proliferation in the Carotid Artery. *Sci Rep* (2018) 8:761. doi: 10.1038/s41598-017-19136-6

65. Krishna SM, Omer SM, Golledge J. Evaluation of the clinical relevance and limitations of current pre-clinical models of peripheral artery disease. *Clin Sci* (2016) 130:127–50. doi: 10.1042/CSS1050435

66. Cooke JP, Losordo DW. Modulating the vascular response to limb ischemia: angiogenic and cell therapies. *Circ Res* (2015) 116:1561–78. doi: 10.1161/CIRCRESAHA.115.303565

67. Ji, P, Saredy J, Xi H, Coman C, Yang W, et al. Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation. *Hematol Oncol* (2017) 10:141. doi: 10.1016/s3415-947-015-9041-0

68. Xu K, Yang WY, Nanayakkara GK, Shao Y, Yang F, Wu H, et al. gaTα3, Hdcα6, and Bcl6 regulate FOXP3+ Treg Plasticity and Determine Treg conversion into either novel antigen-Presenting cell-like Treg or Th1-Treg. *J Immunol* (2019) 161:19. doi: 10.1186/s12290-019-0217-z

69. Krishna SM, Omer SM, Li J, Morton SK, Jores RJ, Golledge J. Development of a two-stage limb ischemia model to better simulate human peripheral artery disease. *Sci Rep* (2020) 10:1–16. doi: 10.1038/s41598-020-06035-2

70. Dai J, Fang P, Saredy J, Xi H, Coman C, Yang W, et al. Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. *J Immunol* (2011) 186:6661–6. doi: 10.4049/jimmunol.20110315

71. Jia D, Ji, H, Weng X, Wu J, Bai P, Yang W, et al. Interleukin-35 promotes macrophage survival and improves wound healing after myocardial infarction in mice. *Circ Res* (2019) 124:1323–36. doi: 10.1161/CIRCRESAHA.118.314569

72. Kivelä R, Hemanthakumar KA, Vaparanta K, Robciuc M, Izumiya Y, Kidoya H, et al. Endothelial cells regulate physiological cardiomyocyte growth via VEGFR2-mediated paracrine signaling. *Circulation* (2019) 139:2570–84. doi: 10.1161/CIRCULATIONAHA.118.036099
87. Deng J, Zhang N, Wang Y, Yang C, Wang Y, Xin C, et al. FNDC5/irisin improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells for myocardial infarction. Stem Cell Res Ther (2020) 11:1–15. doi: 10.1186/s13287-020-01746-z
88. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 85:683–93. doi: 10.1016/S0092-8674(00)81235-0
89. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest (1999) 103:1237–41. doi: 10.1172/JCI6870
90. Raza SL, Cornelius LA. Matrix metalloproteinases: pro- and anti-angiogenic activities. J Invest Dermatol Symp Proc (2000) 5:47–54. doi: 10.1046/j.1087-0024.2000.00004.x
91. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell (1997) 88:801–10. doi: 10.1016/S0092-8674(00)81926-1
92. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett (2000) 486:247–51. doi: 10.1016/S0014-5793(00)02249-3
93. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A (1999) 96:14888–93. doi: 10.1073/pnas.96.26.14888
94. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med (2002) 6:1–12. doi: 10.1011/j.1582-4934.2002.00037.x
95. Weber GF, Bjerke MA, DeSimone DW. Integrins and cadherins join forces to form adhesive networks. J Cell Sci (2011) 124:1183–93. doi: 10.1242/jcs.064618
96. Mui KL, Chen CS, Assoian RK. The mechanical regulation of integrin-cadherin crosstalk organizes cells, signaling and forces. J Cell Sci (2016) 129:1093–100. doi: 10.1242/jcs.183699
97. Wang Y, Jin G, Miao H, Li JY, Usami S, Chien S. Integrins regulate VE-cadherin and catenins: dependence of this regulation on Src, but not on Ras. Proc Natl Acad Sci U S A (2006) 103:1774–9. doi: 10.1073/pnas.0510774103
98. Takahashi N, Ishihara S, Takada S, Tsukita S, Nagauchi A. Posttranscriptional regulation of alpha-catenin expression is required for Wnt signaling in L cells. Biochem Biophys Res Commun (2000) 277:691–8. doi: 10.1006/bbrc.2000.3748
99. Yonemura S, Wada Y, Watanabe T, Nagauchi A, Shibata M. alpha-Catenin as a tension transducer that induces adherens junction development. Nat Cell Biol (2010) 12:533–42. doi: 10.1038/ncb2055
100. Lampugnani MG, Corada M, Caveda L, Brevisario F, Ayalon O, Geiger B, et al. The molecular organization of endothelial cell to cell junctions: differential association of plakoglobin, beta-catenin, and alpha-catenin with vascular endothelial cadherin (VE-cadherin). J Cell Biol (1995) 129:203–17. doi: 10.1083/jcb.129.1.203
101. Zhou X, Xia N, Lv B, Tang T, Nie S, Zhang M, et al. Interleukin 35 ameliorates myocardial ischemia-reperfusion injury by activating the gp130-STAT3 axis. FASEB J (2020) 34:3224–38. doi: 10.1096/fj.201901718RR

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Fu, Sun, Shao, Saredy, Cueto, Liu, Drummer, Johnson, Xu, Lu, Li, Meng, Xue, Tan, Huala, Yu, Zhou, Bayless, Yu, Rogers, Hu, Snyder, Sun, Qin, Jiang, Wang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.